HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) and QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN N.V. (Nasdaq: QGEN). This Agreement creates a framework for both companies to combine their technological and commercial strengths with the goal to offer pharmaceutical companies a complete NGS-based solution for the development and commercialization of companion diagnostics, with a focus in oncology. Together with the parties’ entry into the Agreement, QIAGEN North American Holdings, Inc., another QIAGEN subsidiary, made a minority investment in HTG’s common stock.
{iframe}http://www.streetinsider.com/Corporate+News/HTG+Molecular+Diagnostics+(HTGM),+QIAGEN+(QGEN)+Unit+to+Develop+NGS-Based+Diagnostics+Solution/12255742.html{/iframe}